Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL235 Target Snapshot

Peroxisome proliferator-activated receptor gamma · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
8,182Compounds
1,793Assays
32Approved Drugs
8,450.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Peroxisome proliferator-activated receptor gamma shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 14 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P37231. Start with type 2 diabetes mellitus, then reuse UniProt P37231 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with type 2 diabetes mellitus, then reuse UniProt P37231 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 14 linked drugs
Open source guide
Disease program
type 2 diabetes mellitus

Peroxisome proliferator-activated receptor gamma shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 14 linked drugs remain visible in the same block.

Start review with type 2 diabetes mellitus because it currently carries approved-linked support. Linked drugs include ALEGLITAZAR, ARHALOFENATE, BALAGLITAZONE, INT131. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 14 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Peroxisome proliferator-activated receptor gamma as ChEMBL target CHEMBL235, mapped to UniProt P37231. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Peroxisome proliferator-activated receptor gamma
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL235
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P37231
Peroxisome proliferator-activated receptor gamma
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Peroxisome proliferator-activated receptor gamma is the right protein anchor across sources, using UniProt P37231 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why type 2 diabetes mellitus is currently framed as approved-linked support. It currently carries 14 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NamePeroxisome proliferator-activated receptor gamma
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP37231
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPeroxisome proliferator-activated receptor gamma
UniProt AccessionP37231
Component TypeProtein
Sequence Length505 aa

Peroxisome proliferator-activated receptor gamma

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Peroxisome proliferator-activated receptor gamma, mapped to UniProt P37231. Sequence length is 505 aa.

Mapped IDP37231
Review namePeroxisome proliferator-activated receptor gamma
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Peroxisome proliferator-activated receptor gamma shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
type 2 diabetes mellitus
14 linked drugs · 14 direct · 14 efficacy
Linked drugALEGLITAZAR
Linked drugARHALOFENATE
Linked drugBALAGLITAZONE
Linked drugINT131
Approved-linked Approved
diabetes mellitus
7 linked drugs · 7 direct · 7 efficacy
Linked drugATX08-001
Linked drugIMIGLITAZAR
Linked drugMK-0767
Linked drugMURAGLITAZAR
Approved-linked Approved
ulcerative colitis
4 linked drugs · 4 direct · 4 efficacy
Linked drugBALSALAZIDE DISODIUM
Linked drugMESALAMINE
Linked drugOLSALAZINE SODIUM
Linked drugROSIGLITAZONE
Approved-linked Approved
proctitis
1 linked drug · 1 direct · 1 efficacy
Linked drugMESALAMINE
Late clinical Phase III
Disorder of lipid metabolism
3 linked drugs · 3 direct · 3 efficacy
Linked drugMURAGLITAZAR
Linked drugROSIGLITAZONE
Linked drugSAROGLITAZAR
Late clinical Phase III
inflammatory bowel disease
3 linked drugs · 3 direct · 3 efficacy
Linked drugBALSALAZIDE DISODIUM
Linked drugMESALAMINE
Linked drugROSIGLITAZONE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with type 2 diabetes mellitus because it currently carries approved-linked support. Linked drugs include ALEGLITAZAR, ARHALOFENATE, BALAGLITAZONE, INT131. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasetype 2 diabetes mellitus
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

32
Approved
27
Phase III
37
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC502,321.0
KI622.0
EC505,401.0
KD106.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1813011 10.74 EC50 0.018 Preclinical
CHEMBL3545280 10.42 EC50 0.038 Clinical
CHEMBL1813008 10.3 EC50 0.05 Preclinical
CHEMBL434063 10.3 Ki 0.0497 Preclinical
CHEMBL3678131 10.22 IC50 0.06 Preclinical
CHEMBL358379 10.0 EC50 0.1 Preclinical
CHEMBL230814 10.0 EC50 0.1 Preclinical
CHEMBL2282517 10.0 EC50 0.1 Preclinical
CHEMBL3317860 10.0 Kd 0.1 Preclinical
CHEMBL3695832 10.0 IC50 0.1 Preclinical
Distribution

pChEMBL Value Distribution

905
5.0
1107
5.5
1063
6.0
927
6.5
778
7.0
630
7.5
441
8.0
231
8.5
136
9.0
23
9.5
pChEMBL
Approved Drugs

Approved Drugs

ELAFIBRANOR
CHEMBL3707395
Approved 2024
Properties Compare Identifier
ROSIGLITAZONE
CHEMBL121
Approved 1999
Properties Compare Identifier
PIOGLITAZONE
CHEMBL595
Approved 1999
Properties Compare Identifier
ROSIGLITAZONE MALEATE
CHEMBL843
Approved 1999
Properties Compare Identifier
TELMISARTAN
CHEMBL1017
Approved 1998
Properties Compare Identifier
TROGLITAZONE
CHEMBL408
Approved 1997
Properties Compare Identifier
FENOFIBRATE
CHEMBL672
Approved 1993
Properties Compare Identifier
GLYBURIDE
CHEMBL472
Approved 1984
Properties Compare Identifier
LEVOTHYROXINE
CHEMBL1624
Approved 1982
Properties Compare Identifier
LIOTHYRONINE
CHEMBL1544
Approved 1956
Properties Compare Identifier
Assay Landscape

Assay Landscape

1,793
Total Assays
3,864
Tested Compounds
4
Assay Types
Binding — 1,413 assays, 3,864 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 727 1,605 6.2
single protein format 555 2,046 6.7
assay format 114 213 6.2
tissue-based format 17 0 —
Functional — 362 assays, 1,750 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 247 1,030 6.7
assay format 115 720 6.8
ADME — 17 assays, 24 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 13 18 6.2
single protein format 4 6 4.8
Toxicity — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine